Earnings

Damora Therapeutics Q2 EPS $(0.39) Beats $(0.43) Estimate

Aug 10, 2026 · 04:54 PM ET· updated 1h ago

Damora Therapeutics (NASDAQ:DMRA) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.43) by 9.3 percent. This is a 85 percent increase over losses of $(2.60) per share from

Why It Matters

Damora lost less money per share than experts expected, which is good news. When a company that's still losing money does better than people thought, it shows the business is improving.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

DMRA29.61

-0.32 (-1.05%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.